Spotlight in Focus: Opioid Crisis Demands Psychedelic Innovation, Yesterday
This month’s “Spotlight in Focus” features candid conversation with an opioid addict, and the director writes how psychedelic therapy can help.
This month’s “Spotlight in Focus” features candid conversation with an opioid addict, and the director writes how psychedelic therapy can help.
This week in psychedelic business news: Field Trip partners with Cerebral; Benzinga forms Psychedelic Advisory Council; Incannex pursues virtual reality psychedelic therapy.
A year after a Johns Hopkins psilocybin-assisted therapy study, researchers find the number of people who benefited from receiving two doses actually increased.
Spoiler alert: It’s not because they’re depressed.
Matthew X. Lowe, Ph.D., the Research Director of Unlimited Sciences, explains why observational research is the key for eventual legalization of psychedelic drugs.
“Considering all our advocacy on this issue, this employee benefit is the next logical step,” says company president Michael Bronner.
And 94% reported meeting with otherworldly beings during “profound and highly intense experiences.”
How long until Psychedelic Stocks Payoff?🍄🚀
To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
While researching a possible investment into psychedelic stocks, you have almost certainly heard the refrain of, “It’s a long-term investment.” I myself, in my many videos for The Psychedelic Investor and articles for PsychedelicSpotlight.com, have probably said this over 100 times.
And while the thesis for investing in psychedelic stocks is appealing, having a timeline clearer than “it’s a long term investment” is necessary before deciding whether it is worth the risk.
In this video, therefore, I endeavor to answer a big question: “When will psychedelic stocks provide a significant return on investment?”
Or, translated to Reddit-speak: when moon?
To start, I feel it’s necessary to give the warning that the answer may be never. To be clear, while I personally believe in the potential for psychedelic stocks such as MindMed (Nasdaq: MNMD, NEO: MMED) and Cybin (NYSE: CYBN, NEO: CYBN), the entire psychedelic medicines industry is inherently speculative and there is no guarantee of success. Yes, the science right now suggests that treatments such as MDMA therapy for PTSD and Ketamine therapy for addiction will disrupt the mental healthcare market, but this needs to be confirmed in larger studies.
There will be two separate turning points for psychedelic medicines and the companies that produce them: the legalization of the first psychedelic medicines, and the legalization of improved next-generation psychedelics.
The first will happen relatively soon.
#PsychedelicStocks #MindMed #Cybin
This week in psychedelic business news: Core One cheapens psilocybin production; Field Trip eyes Oregon; Small Pharma advances DMT.
Another study concludes with results challenging the increasingly popular narrative that microdosing psychedelics improves mood and cognitive function.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.